Multidomain Treatment for Mild TBI: What a 2026 Randomized Trial Found

Mild traumatic brain injury is the most common form of brain injury, and it accounts for the majority of TBI cases. It is also the area where treatments are most often promoted on the strength of weaker evidence. So a properly randomised trial is worth reading carefully.

What the trial tested

A randomised trial published in JAMA Network Open compared targeted multidomain treatment against a control condition in people with mild traumatic brain injury. A total of 162 participants were randomised, 81 to each group, with a mean age of 29 and a majority female enrollment.

The design reflects a practical view of concussion: symptoms are not one thing. Headache, sleep disturbance, dizziness, mood change and cognitive difficulty can each need a different response, and treating only one of them may leave the rest untouched. Multidomain treatment addresses several at once, targeted to the individual.

That is the same reasoning behind a study of a customized rehabilitation program, published in PubMed, in which participants made a clinically meaningful and statistically significant change on primary and secondary outcome measures at six weeks, with those changes maintained at twelve weeks.

What the results showed

The trial reported that both groups experienced similar improvements on some measures, with between-group differences that were small on the outcomes examined. This is a familiar and important pattern in concussion research.

It does not mean the treatment failed. It means that a well-run control condition — which usually involves structured assessment, clear information, and follow-up — produces real improvement in many people. That is exactly why informal reassurance and uncontrolled clinic reports overstate what a specific intervention adds.

Two other lines of evidence

Photobiomodulation. A study published in Journal of Neurotrauma reported that transcranial photobiomodulation improved cognitive function, post-concussion symptoms and PTSD symptoms in mild TBI. This is a small, early-phase area of research; promising results in a pilot setting do not establish a treatment.

Hyperbaric oxygen. A randomised placebo-controlled trial of mild hyperbaric oxygen for persistent post-concussive symptoms, reported at 13-week follow-up, found no significant differences between intervention and placebo groups in serum levels of several biomarkers of neuronal injury. A null result here is genuinely informative: it narrows what a popular but contested intervention can be said to do.

The honest position

For someone with a concussion, the evidence supports a structured, symptom-targeted approach with clear follow-up, and it does not support the idea that any single device or supplement is the answer.

• A good control condition produces real improvement, which is why uncontrolled reports overstate effects.
• Multidomain, individualised care is where the research is converging.
• Novel physical treatments remain experimental; some early positive signals have not survived placebo-controlled testing.

This article is educational and is not medical advice. Seek medical assessment after any head injury.